-- 加拿大国家银行周五维持对Real Matters（REAL.TO）股票的“与行业持平”评级，并将目标股价从7.00加元上调至7.50加元。此前，该公司公布第二财季实现合并净利润。 分析师表示，该公司在美国产权业务方面持续拓展客户，其中许多客户来自其庞大的美国评估客户群。该公司在第二财季新增了四家客户，包括一家大型非银行服务机构。季度结束后，该公司又与一家一级贷款机构和另一家排名前100的贷款机构签署了合作协议。 这一增长势头推动了公司强劲增长，净收入同比增长176%至330万美元，调整后EBITDA由上年同期的-210万美元改善至-40万美元。分析师补充道，尽管产权业务目前约占总净收入的25%，但其规模有望达到评估业务的水平。分析师表示：“总而言之，我们认为第二财季业绩稳健，反映了公司在扩大美国产权业务规模、提升市场份额（涵盖评估和产权业务）以及提高运营杠杆方面取得的成效。尽管如此，利率环境的不确定性仍然使其风险回报比保持平衡。”
Related Articles
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.
$MRNA
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.
$GEHC
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.
$LII